Blood test determines cancer treatment: less chemo for some, more for others
NCT ID NCT07154069
Summary
This large Phase 3 trial is testing a personalized treatment strategy for advanced nasopharyngeal cancer. After initial chemo-immunotherapy, patients are split into two groups based on a blood test for EBV-DNA. Low-risk patients receive less intensive treatment (radiation only) to reduce severe nausea, while high-risk patients receive intensified treatment (extra chemo and immunotherapy) to try to improve survival. The goal is to match treatment intensity to individual risk to get the best outcomes with the fewest side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CANCINOMA (NPC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
RECRUITINGGuangzhou, Guangdong, 510060, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.